panitumumab,bevacizumab
amgen,roche,takeda
['rectal', 'paradigm', 'colorectal']
paradigm trial: 1st-l treatment in patients with ras wild-type metastatic colorectal cancer pan + mfolfox6 &gt;&gt; bev + mfolfox6, hr 0.82 for os (in left-sided tumors) no difference for pfs better r0 and dor with panitimumab omics analysis awaited #asco22 
Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni